<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01341964</url>
  </required_header>
  <id_info>
    <org_study_id>11-090</org_study_id>
    <nct_id>NCT01341964</nct_id>
  </id_info>
  <brief_title>Clopidogrel and Aspirin Interaction Study-2</brief_title>
  <acronym>Interaction2</acronym>
  <official_title>Randomized Controlled Trial to Explore Interaction Between Aspirin and Clopidogrel in Stable Patients With Previous Myocardial Infarction or Coronary Artery Stent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Population Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Population Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clopidogrel and aspirin are commonly used in combination to prevent heart attacks and to
      prevent blockage of stents. Both clopidogrel and aspirin work by preventing platelets (sticky
      cells that circulate in the blood) from forming blood clots in the arteries supplying oxygen
      to the heart and in stents. The investigators hypothesize that aspirin 325mg compared with
      aspirin 81 mg will increase blood levels of the active metabolite of clopidogrel in patients
      with a history of coronary artery disease who receive a 600mg loading dose of clopidogrel.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients will be randomized to receive clopidogrel 600mg + aspirin 325mg (Group A)
      or clopidogrel 600mg + aspirin 81mg (Group B). Patients will be fasted for at least 8 hours
      prior to study drug administration. Blood samples will be collected at 1 hour after study
      drug administration for measurement of clopidogrel active metabolite levels and genotyping.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood concentration of the active metabolite of clopidogrel</measure>
    <time_frame>1 hour after loading dose of study medications</time_frame>
    <description>Clopidogrel active metabolite concentration will be measured by liquid chromatography tandem mass spectrometry (LC/MS) methods.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Drug Action Increased</condition>
  <arm_group>
    <arm_group_label>Higher dose aspirin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clopidogrel 600 mg plus aspirin 325mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose aspirin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clopidogrel 600mg plus aspirin 81mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>600mg (2 pills)</description>
    <arm_group_label>Higher dose aspirin group</arm_group_label>
    <arm_group_label>Low dose aspirin group</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>325mg (1 pill)</description>
    <arm_group_label>Higher dose aspirin group</arm_group_label>
    <other_name>Novasen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>81mg (1 pill)</description>
    <arm_group_label>Low dose aspirin group</arm_group_label>
    <other_name>Entrophen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stable patients &gt;1 month post ACS (including ST elevated myocardial infarction, non-ST
             elevated myocardial infarction or unstable angina) or stent

          -  Receiving regular ASA (81mg/d) and clopidogrel (75mg/d) for at least 1 week

          -  Written informed consent

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  Liver disease with ALT or bilirubin &gt;2x upper limits of normal (ULN)*

          -  Renal impairment with creatinine clearance &lt;30 ml/min*

          -  Deemed to be at high risk of bleeding (e.g., recent bleeding, platelet count&lt;100x109/L
             or hemoglobin &lt;100g/L)*

          -  Anticoagulant or NSAID therapy within the last 5 days

          -  Antiplatelet agent other than aspirin and clopidogrel within the last 10 days

          -  Uncontrolled hypertension (&gt;=180/110mmHg)

               -  within 3 months of planned randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yan Liang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Population Health Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Eikelboom, MD</last_name>
    <role>Study Director</role>
    <affiliation>Population Health Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Population Health Research Institute, Hamilton General Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2011</study_first_submitted>
  <study_first_submitted_qc>April 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2011</study_first_posted>
  <last_update_submitted>April 27, 2015</last_update_submitted>
  <last_update_submitted_qc>April 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Population Health Research Institute</investigator_affiliation>
    <investigator_full_name>John Eikelboom</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>Clopidogrel</keyword>
  <keyword>Aspirin</keyword>
  <keyword>Interaction</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

